Sol-Gel And Mayne Pharma Announce The Purchase Of Epsolay And Twyneo In The U.S.
April 17 (Reuters) - Mayne Pharma Group Ltd MYX.AX:
SOL-GEL AND MAYNE PHARMA ANNOUNCE THE PURCHASE OF EPSOLAY® AND TWYNEO® IN THE U.S.
SOL-GEL- TO RECEIVE $16 MILLION DURING 2025
SOL-GEL- SGT-610 PHASE III TRIAL TOP-LINE RESULTS EXPECTED Q4 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

WTI and Brent Futures Both Fall Below $100 Mark, Have Oil Prices and Energy Sector Peaked?

Tradingkey








